Antimicrobial Regimen and Safety of Pediatric Outpatient Treatment in a POIC

SUGAR LAND, TX (January 25, 2016) – Pediatric outpatient antimicrobial therapy (OPAT) is increasing, however, data on management, safety, and clinical outcomes are limited. A two-year retrospective, observational study was conducted of 64 pediatric patients receiving intravenous antibiotics for various diagnoses across 20 nationwide physician office infusion centers (POIC). Patient characteristics evaluated included demographics, diagnosis, antimicrobial usage, microbiology, clinical outcomes, and complications.

The most frequently treated diagnoses were cellulitis and abscess (n=18), osteomyelitis (n=11), and complicated intra-abdominal infections (n=9). Most commonly used antimicrobials were ceftriaxone (n=20), vancomycin (n=10), and ertapenem (n=9) with a mean length of therapy of 21 days. One-third of the pediatric patients received OPAT without prior hospitalization. Therapy-related adverse events occurred in 30 percent of patients, all of which were successfully managed in the infusion center. Clinical success was achieved in all patients, including 78 percent cured and 22 percent discharged with continued oral antibiotics.

This study demonstrated that OPAT in a POIC is a safe and effective option for the management of a variety of pediatric infections. To learn more, click here.

This study was presented at IDWeek 2015™. For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected].


Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

ABOUT IDWeek 2015™

IDWeek 2015™ is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2015 took place October 7-11 at the San Diego Convention Center in San Diego, California. For more information, visit www.idweek.org.

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.